Skip to main content
    F

    Fate Therapeutics Inc (FATE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.02
    -0.12 (-10.53%)

    Market Cap: $138.71M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Fate Therapeutics Inc (FATE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Fate Therapeutics (FATE) has a market cap of $138.71M and an enterprise value of $164.15M. It kept -2619.64% of revenue as net income over the last 12 months. Revenue fell 33.45% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 18.34% above the market cap, as debt exceeds cash.

    Market Cap$138.71M
    Enterprise Value$164.15M
    Latest price (Nov 17, 2026)$1.02

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.71% in the quarter ended Sep 30, 2026 and grew 2.47% a year over 2 years.

    Shares Outstanding123.66M
    Shares Change (YoY)+3.91%
    Shares Change (QoQ)+2.71%
    Share Count Growth (2Y CAGR)+2.47%

    Valuation Ratios

    Sales and book value multiples are 26.6x and 0.9x. Its year-end P/S ranged from 5.8x to 245.1x from 2016 to 2025.

    P/S Ratio26.6x
    Forward P/S39.2x
    P/B Ratio0.9x

    Valuation history and multiples

    Price Statistics

    The stock is up 5.81% over 52 weeks and trades 51.43% below its 50-day average.

    Beta (1Y)2.31
    52-Week Change+5.81%
    1-Month Change-45.16%
    3-Month Change-61.51%
    6-Month Change-46.03%
    5-Year Change-96.13%
    10-Year Change-0.95%
    Total Return (1Y)+5.81%
    Total Return (3Y CAGR)-25.12%
    Total Return (5Y CAGR)-54.98%
    Return vs SPY (1Y)-11.56%
    Max Drawdown (1Y)-67.20%
    Max Drawdown (3Y)-91.86%
    Sharpe Ratio (1Y)0.00
    Correlation with SPY (1Y)0.35
    50-Day Average$2.10
    200-Day Average$1.98
    52-Week Range$0.95 to $3.23
    RSI (14 Days)19.3
    Average Volume (20 Days)1.66M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.41x current liabilities, and total debt is 0.52x shareholder equity.

    Current Ratio4.41x
    Quick Ratio4.41x
    Debt / Equity0.52x

    Returns and Efficiency

    Return on invested capital is -51.32% over the last 12 months, against a 5-year average of -35.15%.

    Return on Equity (ROE)-93.54%
    Return on Assets (ROA)-52.22%
    Return on Invested Capital (ROIC)-51.32%
    ROE (5Y Average)-51.48%
    ROA (5Y Average)-35.95%
    ROIC (5Y Average)-35.15%
    Asset Turnover0.02x
    Receivables Turnover8.04x

    Scores

    FATE has an Altman Z-Score of -10.08, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-10.08
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $4.75M over the last 12 months.

    Revenue$4.75M
    Revenue Growth (YoY)-33.45%
    Gross Profit$4.75M
    Operating Income-$131.10M
    Pretax Income-$124.43M
    Net Income-$124.43M
    EBITDA-$123.18M
    Reported EPS (TTM)-$1.03

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 55.83% of the $238.28M in total assets.

    Cash and Equivalents$43.94M
    Total Debt$69.38M
    Net Debt$25.44M
    Net Debt Per Share$0.21
    Working Capital$111.57M
    Shareholder Equity$133.03M
    Book Value Per Share$1.08
    Total Assets$238.28M
    Total Liabilities$105.24M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$105.46M
    FCF Per Share-$0.89
    Depreciation and Amortization$14.58M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2760.04%.

    Gross Margin100.00%
    Operating Margin-2760.04%
    Pretax Margin-2619.64%
    Net Margin-2619.64%
    EBITDA Margin-2593.35%

    Growth

    Revenue fell 58.98% a year over 3 years.

    Revenue Growth (3Y CAGR)-58.98%
    Revenue Growth (5Y CAGR)-26.71%
    Book Value Per Share Growth (2Y CAGR)-31.67%
    Tangible Book Per Share Growth (2Y CAGR)-31.67%

    Revenue and profit by year

    Dividends and Yields

    FATE does not pay a dividend.

    Buyback Yield0.00%
    Shareholder Yield0.00%

    Peer Position

    Against 7 similar companies, FATE has the highest P/S.

    P/S Ratio26.6x vs 4.0x median
    ROIC-51.32% vs -149.78% median
    Revenue Growth (Trailing 4 Quarters, YoY)-33.45% vs -28.56% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -31.96% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-31.96%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About FATE

    What is FATE's market cap?

    Fate Therapeutics has a market cap of $138.71M. Its enterprise value, which adds debt and subtracts cash, is $164.15M.

    How many shares of FATE are outstanding?

    Fate Therapeutics has 123.66M shares outstanding. The count is up 3.91% from a year earlier.

    Does FATE pay a dividend?

    No. Fate Therapeutics does not pay a dividend.

    How much debt does FATE have?

    Fate Therapeutics has $69.38M of total debt and $43.94M of cash and equivalents, a net debt position of $25.44M.